REMARKS

Claims 1-6 have been amended prior to examination, claims 7 and 8 have been cancelled without prejudice and claims 9 and 10 have been added. These amendments were made in order to make corrections to the claim sentence structure for grammatical purposes, to eliminate the term "optionally" and to eliminate brackets used in chemical names, and not for purposes of patentability under 35 USC 101,102,103 or 112. It is respectively submitted that no estoppel is created by this amendment.

Respectfully submitted,

William M. Blackstone
Attorney for Applicants
Registration No. 29,772

Attorney Docket No. O/98411 US
Akzo Nobel Patent Department
1300 Piccard Drive, Suite 206
Rockville, Maryland 20850
Tel: (301) 948-7400
Fax: (301) 948-9751

WMB:lcf
41TIMMERS PRE-AMENDMENT

1. (Amended) [Serine] A serine protease inhibitor having the formula (I),



in which

J is H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO-$(CHR^2)_p$-;

D is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-CH[[]((CH_2)$_q$C(O)OR^1[]])-C(O)-, -NR^4-CH[[]((CH_2)$_q$C(O)$N(R^{2a},R^{2b})$[]])-C(O)-, -NR^4-CH[[]((CH_2)$_q$C(O)Het[]])-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq or D-3 Piq;

E is -NR^2-CH_2- or the fragment

, [optionally] which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R^1 is selected form (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups [may optionally be] are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF_3 or halogen, and from

(6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and

(14-20C)(bisaryl)alkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2, R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which [can each be optionally] are unsubstituted or substituted with (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is [as defined for] the same as R^2 or is Het-(1-6C)alkyl;

R^4 is H or (1-3C)alkyl;

X and Y are CH or N, with the proviso that they are not both N;

Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S;

m is 1 or 2;

p is 1, 2 or 3;

q is 1, 2 or 3;

t is 2, 3 or 4;

[or a prodrug;]

[and/or] or a pharmaceutically acceptable addition salt [and/or] or solvate thereof.

2. (Amended) [Serine] The serine protease inhibitor according to claim 1, wherein m is 2; X is CH and Y is CH.

3. (Amended) The serine protease inhibitor according to claim 2, wherein

J is H, R^1 R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO$(CHR^2)p$-;

D is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-CH[[]([$(CH_2)_q$C(O)OR^1[]])-C(O)-, -NR^4-CH[[]([$(CH_2)_q$C(O)$N(R^{2a},R^{2b})$[]])-C(O)-,

E is -N(3-6C)cycloalkyl-CH_2- or the fragment



, [optionally] which is unsubstituted or substituted with (1-6C)alkyl or (1-6C)alkoxy;

R^1 is selected from (1-12C)alkyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups [may optionally be] are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2 is H;

[redacted]

R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloakyl(1-4C)alkylene, which [can each be optionally] are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy and from (6-14C)aryl and (7-15C)aralkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which [can each be optionally] are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl;

p is 1;

q is 2;

t is 3 or 4.

4. (Amended) [Serine] The serine protease inhibitor according to claim 3, wherein

D is an amino-acid of the formula $-NH-CHR^1-C(O)-$ or glutamyl[[] or an (1-6C)alkylester thereof[]];

R^1 is selected from (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups [may optionally be] are unsubstituted or substituted with (3-12C)cycloalkyl or (1-6C)alkoxy, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisary)alkyl, [whereby]

wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or halogen; and

R^3 is selected from (1-8C)alkyl and (3-8C)cycloalkyl, which [can each be optionally] are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, [whereby] wherein the aryl groups [may optionally be] are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl.

5. (Amended) [Serine] The serine protease inhibitor according to claim 4, wherein

J is $-CH_2COO$(1-6C)alkyl, (3-8C)cycloalkyl, $-SO_2$-10-camphor, $-CH_2CONH$phenyl or $-CH_2CONH$(3-8C)cycloalkyl;

D is D-cyclohexylalaninyl, D-phenylalaninyl, D-diphenylalaninyl or glutamyl, [[]or an (1-6C)alkylester thereof[]]; and

E is the fragment



, wherein t is 3 or 4.

6. (Amended) A pharmaceutical composition comprising the serine protease inhibitor of [any one of claims 1 to 5] claim 1 and at least one pharmaceutically suitable [auxiliaries] auxiliary.